Literature DB >> 8961510

DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

N Bourne1, G N Milligan, M R Schleiss, D I Bernstein, L R Stanberry.   

Abstract

The immunogenicity and protective efficacy of a nucleic acid vaccine encoding the herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) gene under the control of the CMV immediate early gene promoter was examined. Mice immunized three times by intramuscular injection with the vaccine developed an HSV specific IgG but not IgA antibody response detectable in both serum and vaginal secretions. In addition, antigen-specific cellular immune responses were detected in splenic lymphocytes isolated from DNA immunized animals. Immunization reduced virus replication in the genital tract following a lethal intravaginal HSV-2 challenge. Furthermore, symptomatic genital HSV disease was reduced in immunized mice and the animals were completely protected from death. We conclude that a nucleic acid vaccine expressing HSV-1 gD induced both humoral and cell mediated immune responses in mice which proved highly protective against disease following virus challenge.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961510     DOI: 10.1016/s0264-410x(96)00027-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  Control of STDs--the role of prophylactic vaccines against herpes simplex virus.

Authors:  L R Stanberry
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Immunization of the female genital tract with a DNA-based vaccine.

Authors:  J B Livingston; S Lu; H Robinson; D J Anderson
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

4.  Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease.

Authors:  Ayuko Sato; Aldina Suwanto; Manami Okabe; Shintaro Sato; Tomonori Nochi; Takahiko Imai; Naoto Koyanagi; Jun Kunisawa; Yasushi Kawaguchi; Hiroshi Kiyono
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

5.  Estradiol improves genital herpes vaccine efficacy in mice.

Authors:  Jeffry W Pennock; Rachael Stegall; Brent Bell; Gracie Vargas; Massoud Motamedi; Gregg Milligan; Nigel Bourne
Journal:  Vaccine       Date:  2009-08-04       Impact factor: 3.641

6.  A mucosal vaccination approach for herpes simplex virus type 2.

Authors:  Rebecca S Tirabassi; Christopher I Ace; Tatyana Levchenko; Vladimir P Torchilin; Liisa K Selin; Siwei Nie; Dennis L Guberski; Kejian Yang
Journal:  Vaccine       Date:  2010-12-04       Impact factor: 3.641

7.  Use of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cells.

Authors:  Ronen Borenstein; Oded Singer; Adi Moseri; Niza Frenkel
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.

Authors:  Hanka Augustinova; Daniela Hoeller; Feng Yao
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 9.  Herpes simplex virus type 2 vaccines: new ground for optimism?

Authors:  L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

10.  Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases.

Authors:  Mika Kamata; Kaori Denda-Nagai; Nobuyoshi Kubota; Satoshi Aida; Kazuyoshi Takeda; Tatsuro Irimura
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.